IMGN529 is an anti-CD37-maytansinoid conjugate with potent in vitro and in vivo activity against NHL and CLL cell lines

被引：0

作者：

Mayo, Michele F. ^{[1
]}

Li, Min ^{[1
]}

Yi, Yong ^{[1
]}

Xu, Shanqin ^{[1
]}

Lai, Katharine C. ^{[1
]}

Erickson, Hans K. ^{[1
]}

Deckert, Jutta ^{[1
]}

Park, Peter U. ^{[1
]}

Lutz, Robert J. ^{[1
]}

Pinkas, Jan ^{[1
]}

机构：

[1] ImmunoGen Inc, Waltham, MA USA

来源：

CANCER RESEARCH | 2011年 / 71卷

关键词：

D O I：

10.1158/1538-7445.AM2011-4581

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4581

引用

页数：2

共 43 条

[21] Chimeric, divalent and tetravalent anti-CD19 monoclonal antibodies with potent in vitro and in vivo antitumor activity against human B-cell lymphoma and pre-B acute lymphoblastic leukemia cell lines
Liu, Xiao-Yun
Pop, Laurentiu M.
Tsai, Lydia
Pop, Iliodora V.
Vitetta, Ellen S.
INTERNATIONAL JOURNAL OF CANCER, 2011, 129 (02) : 497 - 506
[22] SAR650984, a humanized anti-CD38 antibody, shows potent in vitro activity by multiple mechanisms against various hematologic tumor cell lines.
Deckert, Jutta
Yi, Yong
Chicklas, Sharon
Mayo, Michele
Chittenden, Thomas
Park, Peter
CANCER RESEARCH, 2009, 69
[23] High Frequency of CD74 Expression in B-Cell Non-Hodgkin's Lymphoma (NHL) and Targeting with STRO-001, a Novel Anti-CD74 Antibody Drug Conjugate (ADC) with Potent I n Vitro Cytotoxicty and In Vivo Anti-Tumor Activity
Yu, Abigail
Abrahams, Cristina
Embry, Millicent
Li, Xiaofan
Zhao, Shuchun
Henningsen, Robert
DeAlmeida, Venita
Matheny, Shannon
Kline, Toni
Yam, Alice
Stafford, Ryan
Natkunam, Yasodha
Hallam, Trevor
Lupher, Mark
Molina, Arturo
BLOOD, 2017, 130
[24] A novel anti-CD20 IgG-IFNα2β conjugate with potent in vitro and in vivo anti-lymphoma activity made by the dock-and-lock (DNL) method
Rossi, E. A.
Cardillo, T.
Nordstrom, D.
Goldenberg, D. M.
Chang, C-H
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2008, 23 (04) : 518 - 519
[25] Anti-tumor activity of emodin against human chronic myelocytic leukemia K562 cell lines in vitro and in vivo
Chun-Guang, Wang
Jun-Qing, Yang
Bei-Zhong, Liu
Dan-Ting, Jin
Chong, Wang
Liang, Zhong
Dan, Zhu
Yan, Wu
EUROPEAN JOURNAL OF PHARMACOLOGY, 2010, 627 (1-3) : 33 - 41
[26] In vitro and in vivo evaluation of the beta-emitting lutetium-177labeled anti-CD37 antibody radionuclide conjugate 177Lu-NNV003 in DLBCL, CLL and MCL models
Maaland, Astri F.
Heyerdahl, Helen
O'Shea, Adam
Eiriksdottir, Bergthora
Dahle, Jostein
CANCER RESEARCH, 2018, 78 (13)
[27] The T cell bispecific antibody CD20-TCB shows high in vitro activity against in vivo ibrutinib-treated primary CLL samples
Ysebaert, Loic
Cadot, Sarah
Bordenave, Julie
Largeaud, Laetitia
Bacac, Marina
Klein, Christian
Mary, Anne Quillet
LEUKEMIA & LYMPHOMA, 2020, 61 : 110 - 111
[28] Anti-CD20-Interferon-α Fusion Protein Demonstrates Potent Direct Growth Inhibition, Antibody-Dependent Cellular Cytotoxicity, and Enhanced Complement-Dependent Cytotoxicity Against Human B Cell Lymphomas In Vitro, and Activity Against Multiple Human NHL Xenografts In Vivo
Yamada, Reiko E.
Steward, Kristopher K.
Ngarmchamnanrith, Gataree
Khare, Sanjay
Sachdev, Raj
Grewal, Iqbal
Morrison, Sherie
Timmerman, John M.
BLOOD, 2011, 118 (21) : 1171 - 1172
[29] SGN-CD19B, a Pyrrolobenzodiazepine (PBD)-Based Anti-CD19 Drug Conjugate, Demonstrates Potent Preclinical Activity Against B-Cell Malignancies
Ryan, Maureen C.
Schimpf, Brian
Anderson, Martha
Zeng, Weiping
Emmerton, Kim
Miyamoto, Jamie
Kostner, Heather
Yu, Changpu
Van Epps, Heather
Tatalick, Laurie
Benjamin, Dennis
BLOOD, 2015, 126 (23)
[30] Activity of the potent dual Abl/Src tyrosine kinase inhibitor FB2 against Bcr-Abl positive cell lines in vitro and in vivo
Yuan, Xia
Zhang, Yi
Zhang, Haijing
Jin, Jing
Li, Xiangyan
Liu, He
Feng, Zhiqiang
Chen, Xiaoguang
LEUKEMIA RESEARCH, 2011, 35 (02) : 237 - 242

← 1 2 3 4 5 →